Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

4

Investigational

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Fibroblast growth factor receptor 1

1

Serine/threonine-protein kinase Aurora-A

1

Tyrosine-protein kinase ABL

1

Tyrosine-protein kinase receptor FLT3

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase I

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute myelogenous leukemia

1

Chronic myelogenous leukemia

1

Myelodysplastic syndromes

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Kyowa Pharmaceutical

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

5

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

5

EPA CompTox

5

FDA UNII

5

PUBCHEM

5

ECHA (EC/EINECS)

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

4

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 5 of 5 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

KW-2449

2D9N67F58G

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Tyrosine-protein kinase receptor FLT3

Tyrosine-protein kinase ABL

Fibroblast growth factor receptor 1

Serine/threonine-protein kinase Aurora-A

Conditions:

Myelodysplastic syndromes

Chronic myelogenous leukemia

Acute myelogenous leukemia

KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukaemia patients. KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase with IC50 values of 6.6nM, 14nM, 4nM and 4...

8nM, respectively. KW-2449 has potent growth inhibitory activity against various types of leukaemia by several mechanisms of action. Kyowa Hakko Kirin Pharma Inc. (a US subsidiary of Kyowa Hakko Kirin Co) was developing KW-2449 for the treatment of acute lymphoblastic leukaemia; acute myeloid leukaemia; chronic myeloid leukaemia; myelodysplastic syndromes, but later these studies were discontinued.

N-(3-AMINOPROPYL)MORPHOLINE

9A09425QD6

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

METHOXYACETIC ACID

F11T1H7Q7W

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

BICINE

1J484QFI1O

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

BICINE SODIUM

IH8W456FUR

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1